Koura announces major investment into new ‘greener’ medical propellant production facility in United Kingdom
Koura announces a multimillion-pound sterling investment into a new cGMP Zephex® 152a medical propellant production facility at their Runcorn, UK location.
This investment is part of a program to bring Zephex® 152a from the laboratory to the patient and will provide a scaling-up in production capacity to meet the increasing demands of customers for high purity, medical grade 152a.
The facility is expected to be commissioned and operational by late 2021 and will lead to the creation of a number of highly skilled job opportunities within the local area.
Global Warming Potential (GWP) is a measure of the atmospheric warming potential of a propellant upon release into the atmosphere. Pressurized metered-dose-inhalers (pMDIs) using Zephex® 152a will bring about a greater than 90 percent reduction in GWP compared to current pMDI propellants1.
The use of Zephex® 152a will bring pMDIs to the forefront of ‘green’ portable inhalation medicine delivery technologies.